1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Bacterial Vaginosis - Pipeline Review, H1 2016

Bacterial Vaginosis - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 55 pages

Bacterial Vaginosis - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Bacterial Vaginosis - Pipeline Review, H1 2016’, provides an overview of the Bacterial Vaginosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Vaginosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis
- The report reviews pipeline therapeutics for Bacterial Vaginosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bacterial Vaginosis therapeutics and enlists all their major and minor projects
- The report assesses Bacterial Vaginosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bacterial Vaginosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Bacterial Vaginosis - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bacterial Vaginosis Overview 6
Therapeutics Development 7
Pipeline Products for Bacterial Vaginosis - Overview 7
Pipeline Products for Bacterial Vaginosis - Comparative Analysis 8
Bacterial Vaginosis - Therapeutics under Development by Companies 9
Bacterial Vaginosis - Therapeutics under Investigation by Universities/Institutes 10
Bacterial Vaginosis - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Bacterial Vaginosis - Products under Development by Companies 14
Bacterial Vaginosis - Products under Investigation by Universities/Institutes 15
Bacterial Vaginosis - Companies Involved in Therapeutics Development 16
Alfa Wassermann S.p.A 16
AmVac AG 17
Evofem, Inc. 18
Starpharma Holdings Limited 19
Symbiomix Therapeutics, LLC 20
Bacterial Vaginosis - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Amphora - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
AMV-100 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
astodrimer - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
benzoyl peroxide - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
rifaximin - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
secnidazole - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
subtilosin - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Bacterial Vaginosis - Recent Pipeline Updates 37
Bacterial Vaginosis - Dormant Projects 45
Bacterial Vaginosis - Discontinued Products 46
Bacterial Vaginosis - Product Development Milestones 47
Featured News and Press Releases 47
Jan 11, 2016: Evofem Holdings Announces Successful Completion of Pre-IND Meeting for Amphora 47
Oct 14, 2015: Additional US Patent granted for VivaGel BV 47
Sep 24, 2015: EU Marketing Approval Granted for VivaGel BV 48
Sep 21, 2015: Symbiomix Therapeutics Presents Data at ICAAC/ICC Demonstrating Oral Pharmacokinetics of Lead Product SYM-1219 Administered With and Without Food 48
Aug 27, 2015: Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 49
Aug 06, 2015: Symbiomix Therapeutics' First Pivotal Trial Results for SYM-1219 for Bacterial Vaginosis Presented at IDSOG 50
Jun 09, 2015: Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis 50
May 05, 2015: Symbiomix Therapeutics Announces Positive Results from a Pivotal Phase 2 Trial of SYM-1219 for the Treatment of Bacterial Vaginosis 51
Mar 04, 2015: Symbiomix Therapeutics Studies Show Drug Candidate for Women's Health Infections is Safe and Well-Tolerated 52
Nov 21, 2014: SYM-1219 Chosen as one of the “Top Infectious Disease Projects” to Watch by Therapeutic Area Partnerships 53
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables
Number of Products under Development for Bacterial Vaginosis, H1 2016 7
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Bacterial Vaginosis - Pipeline by Alfa Wassermann S.p.A, H1 2016 16
Bacterial Vaginosis - Pipeline by AmVac AG, H1 2016 17
Bacterial Vaginosis - Pipeline by Evofem, Inc., H1 2016 18
Bacterial Vaginosis - Pipeline by Starpharma Holdings Limited, H1 2016 19
Bacterial Vaginosis - Pipeline by Symbiomix Therapeutics, LLC, H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Bacterial Vaginosis Therapeutics - Recent Pipeline Updates, H1 2016 37
Bacterial Vaginosis - Dormant Projects, H1 2016 45
Bacterial Vaginosis - Discontinued Products, H1 2016 46

List of Figures
Number of Products under Development for Bacterial Vaginosis, H1 2016 7
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Routes of Administration, H1 2016 23
Number of Products by Stage and Routes of Administration, H1 2016 23
Number of Products by Molecule Types, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) ...

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

N-Formyl Peptide Receptor 2 (FMLP Related Receptor I or Formyl Peptide Receptor Like 1 or HM63 or Lipoxin A4 Receptor or RFP or FPR2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘N-Formyl ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.